Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

Executive Summary

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void

You may also be interested in...



Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well

Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period

Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well

Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period

FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal

FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed

Related Content

UsernamePublicRestriction

Register

PS048427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel